NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis → 1970’s computer coder Issues Shocking AI Warning (From InvestorPlace) (Ad) Free SWTX Stock Alerts $42.95 +0.69 (+1.63%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$42.67▼$43.9850-Day Range$40.10▼$52.5052-Week Range$18.00▼$53.92Volume604,117 shsAverage Volume1.11 million shsMarket Capitalization$3.18 billionP/E RatioN/ADividend YieldN/APrice Target$68.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get SpringWorks Therapeutics alerts: Email Address SpringWorks Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside60.3% Upside$68.83 Price TargetShort InterestBearish14.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 14 Articles This WeekInsider TradingSelling Shares$751,500 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.75) to ($3.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 starsMedical Sector680th out of 915 stocksBiological Products, Except Diagnostic Industry111th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about SpringWorks Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.23% of the outstanding shares of SpringWorks Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in SpringWorks Therapeutics has recently decreased by 1.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 1.8 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for SpringWorks Therapeutics this week, compared to 3 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $751,500.00 in company stock.Percentage Held by InsidersOnly 7.61% of the stock of SpringWorks Therapeutics is held by insiders.Read more about SpringWorks Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($4.75) to ($3.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -8.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -8.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SpringWorks Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlace1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.Click here to watch his new video ASAP About SpringWorks Therapeutics Stock (NASDAQ:SWTX)SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More SWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Stock News HeadlinesMay 9, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for SpringWorks Therapeutics, Inc. Raised by HC Wainwright (NASDAQ:SWTX)May 8, 2024 | globenewswire.comSpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceMay 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.May 8, 2024 | americanbankingnews.comSpringWorks Therapeutics (NASDAQ:SWTX) Stock Rating Reaffirmed by HC WainwrightMay 6, 2024 | markets.businessinsider.comStrong Buy Rating for Springworks Therapeutics Amidst Ogsiveo’s Market Success and Robust PipelineMay 6, 2024 | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call TranscriptMay 5, 2024 | seekingalpha.comSpringWorks Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 3, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.May 3, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn SituationMay 2, 2024 | markets.businessinsider.comBuy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising PipelineMay 2, 2024 | investorplace.comSWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024May 2, 2024 | washingtonpost.comSpringWorks Therapeutics: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesMay 1, 2024 | msn.comSpringWorks Therapeutics Q1 2024 Earnings PreviewApril 25, 2024 | seekingalpha.comSpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer ClearApril 24, 2024 | globenewswire.comSpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 19, 2024 | seekingalpha.comSpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire WinnersApril 18, 2024 | globenewswire.comSpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024April 15, 2024 | nasdaq.comSWTX Quantitative Stock AnalysisMarch 17, 2024 | finance.yahoo.comSWTX Apr 2024 70.000 callMarch 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 6, 2024 | finance.yahoo.comSWTX Apr 2024 60.000 putMarch 6, 2024 | finance.yahoo.comSWTX Apr 2024 65.000 callMarch 4, 2024 | globenewswire.comSpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNFebruary 29, 2024 | globenewswire.comSpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid TumorsFebruary 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)See More Headlines Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/09/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees305Year Founded2017Price Target and Rating Average Stock Price Target$68.83 High Stock Price Target$75.00 Low Stock Price Target$52.00 Potential Upside/Downside+57.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,100,000.00 Net MarginsN/A Pretax Margin-1,281.78% Return on Equity-66.48% Return on Assets-57.28% Debt Debt-to-Equity RatioN/A Current Ratio6.85 Quick Ratio6.77 Sales & Book Value Annual Sales$5.45 million Price / Sales594.76 Cash FlowN/A Price / Cash FlowN/A Book Value$10.01 per share Price / Book4.37Miscellaneous Outstanding Shares74,090,000Free Float68,448,000Market Cap$3.24 billion OptionableOptionable Beta0.84 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Francis I. Perier Jr. (Age 64)M.B.A., Chief Financial Officer Comp: $768.24kDr. Badreddin Edris Ph.D. (Age 37)Chief Operating Officer Comp: $1.02MDr. James Cassidy M.D. (Age 64)Ph.D., Chief Medical Officer Comp: $904.25kMr. Michael P. Nofi (Age 53)Chief Accounting Officer Mr. Tai-An Lin Ph.D.Chief Scientific OfficerMs. Kim DiamondVice President of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)General Counsel & Secretary Comp: $568.64kMr. Daniel J. Pichl (Age 40)Chief People Officer Comp: $428.51kMr. Bhavesh Ashar M.B.A. (Age 58)Chief Commercial Officer Comp: $729.62kMore ExecutivesKey CompetitorsImmunocoreNASDAQ:IMCRIovance BiotherapeuticsNASDAQ:IOVAArcellxNASDAQ:ACLXTwist BioscienceNASDAQ:TWSTImmunovantNASDAQ:IMVTView All CompetitorsInsiders & InstitutionsLord Abbett & CO. LLCBought 2,317,810 shares on 5/9/2024Ownership: 3.128%Orion Portfolio Solutions LLCBought 7,124 shares on 5/9/2024Ownership: 0.039%State Board of Administration of Florida Retirement SystemSold 5,140 shares on 5/9/2024Ownership: 0.017%Russell Investments Group Ltd.Bought 55,893 shares on 5/8/2024Ownership: 0.230%ProShare Advisors LLCBought 2,368 shares on 5/8/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions SWTX Stock Analysis - Frequently Asked Questions Should I buy or sell SpringWorks Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SWTX shares. View SWTX analyst ratings or view top-rated stocks. What is SpringWorks Therapeutics' stock price target for 2024? 6 analysts have issued 1 year price objectives for SpringWorks Therapeutics' stock. Their SWTX share price targets range from $52.00 to $75.00. On average, they predict the company's stock price to reach $68.83 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts. How have SWTX shares performed in 2024? SpringWorks Therapeutics' stock was trading at $36.50 at the beginning of the year. Since then, SWTX shares have increased by 17.7% and is now trading at $42.95. View the best growth stocks for 2024 here. When is SpringWorks Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our SWTX earnings forecast. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings results on Thursday, May, 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by $0.01. The firm earned $21 million during the quarter, compared to analysts' expectations of $12.07 million. The business's revenue for the quarter was up 2000.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.18) EPS. What ETFs hold SpringWorks Therapeutics' stock? ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Biotech ETF (XBI). What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI). When did SpringWorks Therapeutics IPO? SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? SpringWorks Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Lord Abbett & CO. LLC (3.13%), Russell Investments Group Ltd. (0.23%), Peregrine Capital Management LLC (0.16%), Mutual of America Capital Management LLC (0.11%), Assenagon Asset Management S.A. (0.07%) and Sei Investments Co. (0.07%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc and Saqib Islam. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does SpringWorks Therapeutics have any subsidiaries? The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..Read More This page (NASDAQ:SWTX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.